246 related articles for article (PubMed ID: 25731664)
1. [Physico-chemical and toxicological profile of gadolinium chelates as contrast agents for magnetic resonance imaging].
Idée JM; Fretellier N; Thurnher MM; Bonnemain B; Corot C
Ann Pharm Fr; 2015 Jul; 73(4):266-76. PubMed ID: 25731664
[TBL] [Abstract][Full Text] [Related]
2. Efficiency, thermodynamic and kinetic stability of marketed gadolinium chelates and their possible clinical consequences: a critical review.
Port M; Idée JM; Medina C; Robic C; Sabatou M; Corot C
Biometals; 2008 Aug; 21(4):469-90. PubMed ID: 18344005
[TBL] [Abstract][Full Text] [Related]
3. The role of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: A critical update.
Idée JM; Fretellier N; Robic C; Corot C
Crit Rev Toxicol; 2014 Nov; 44(10):895-913. PubMed ID: 25257840
[TBL] [Abstract][Full Text] [Related]
4. Role of thermodynamic and kinetic parameters in gadolinium chelate stability.
Idée JM; Port M; Robic C; Medina C; Sabatou M; Corot C
J Magn Reson Imaging; 2009 Dec; 30(6):1249-58. PubMed ID: 19938037
[TBL] [Abstract][Full Text] [Related]
5. Extracellular gadolinium contrast agents: differences in stability.
Morcos SK
Eur J Radiol; 2008 May; 66(2):175-9. PubMed ID: 18343072
[TBL] [Abstract][Full Text] [Related]
6. Nephrogenic systemic fibrosis: more questions and some answers.
Morcos SK; Thomsen HS
Nephron Clin Pract; 2008; 110(1):c24-31; discussion c32. PubMed ID: 18688172
[TBL] [Abstract][Full Text] [Related]
7. Involvement of gadolinium chelates in the mechanism of nephrogenic systemic fibrosis: an update.
Idée JM; Port M; Dencausse A; Lancelot E; Corot C
Radiol Clin North Am; 2009 Sep; 47(5):855-69, vii. PubMed ID: 19744600
[TBL] [Abstract][Full Text] [Related]
8. Nephrogenic systemic fibrosis-like effects of magnetic resonance imaging contrast agents in rats with adenine-induced renal failure.
Fretellier N; Bouzian N; Parmentier N; Bruneval P; Jestin G; Factor C; Mandet C; Daubiné F; Massicot F; Laprévote O; Hollenbeck C; Port M; Idée JM; Corot C
Toxicol Sci; 2013 Jan; 131(1):259-70. PubMed ID: 22977165
[TBL] [Abstract][Full Text] [Related]
9. Gadolinium-containing MRI contrast agents: important variations on a theme for NSF.
Kuo PH
J Am Coll Radiol; 2008 Jan; 5(1):29-35. PubMed ID: 18180006
[TBL] [Abstract][Full Text] [Related]
10. Gadolinium in Medical Imaging-Usefulness, Toxic Reactions and Possible Countermeasures-A Review.
Blomqvist L; Nordberg GF; Nurchi VM; Aaseth JO
Biomolecules; 2022 May; 12(6):. PubMed ID: 35740867
[TBL] [Abstract][Full Text] [Related]
11. Distribution profile of gadolinium in gadolinium chelate-treated renally-impaired rats: role of pharmaceutical formulation.
Fretellier N; Salhi M; Schroeder J; Siegmund H; Chevalier T; Bruneval P; Jestin-Mayer G; Delaloge F; Factor C; Mayer JF; Fabicki JM; Robic C; Bonnemain B; Idée JM; Corot C
Eur J Pharm Sci; 2015 May; 72():46-56. PubMed ID: 25736527
[TBL] [Abstract][Full Text] [Related]
12. MRI gadolinium-based contrast agents. Radiologists beware!
Goullé JP; Cattanéo A; Saussereau E; Mahieu L; Guerbet M; Lacroix C
Ann Pharm Fr; 2009 Sep; 67(5):335-9. PubMed ID: 19695369
[TBL] [Abstract][Full Text] [Related]
13. Incidence of nephrogenic systemic fibrosis in patients undergoing dialysis after contrast-enhanced magnetic resonance imaging with gadolinium-based contrast agents: the Prospective Fibrose Nephrogénique Systémique study.
Amet S; Launay-Vacher V; Clément O; Frances C; Tricotel A; Stengel B; Gauvrit JY; Grenier N; Reinhardt G; Janus N; Choukroun G; Laville M; Deray G
Invest Radiol; 2014 Feb; 49(2):109-15. PubMed ID: 24169070
[TBL] [Abstract][Full Text] [Related]
14. [Nephrogenic systemic fibrosis].
Breitschaft A; Stahlmann R
Med Monatsschr Pharm; 2009 Oct; 32(10):377-82. PubMed ID: 19886227
[TBL] [Abstract][Full Text] [Related]
15. Effects of gadolinium and gadolinium chelates on intracellular calcium signaling in sensory neurons.
Baykara M; Ozcan M; Bilgen M; Kelestimur H
Neurosci Lett; 2019 Aug; 707():134295. PubMed ID: 31152851
[TBL] [Abstract][Full Text] [Related]
16. Protein-targeted gadolinium-based magnetic resonance imaging (MRI) contrast agents: design and mechanism of action.
Caravan P
Acc Chem Res; 2009 Jul; 42(7):851-62. PubMed ID: 19222207
[TBL] [Abstract][Full Text] [Related]
17. Safety of the Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging, Focusing in Part on Their Accumulation in the Brain and Especially the Dentate Nucleus.
Runge VM
Invest Radiol; 2016 May; 51(5):273-9. PubMed ID: 26945278
[TBL] [Abstract][Full Text] [Related]
18. Clinical and biological consequences of transmetallation induced by contrast agents for magnetic resonance imaging: a review.
Idée JM; Port M; Raynal I; Schaefer M; Le Greneur S; Corot C
Fundam Clin Pharmacol; 2006 Dec; 20(6):563-76. PubMed ID: 17109649
[TBL] [Abstract][Full Text] [Related]
19. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C.
Frenzel T; Lengsfeld P; Schirmer H; Hütter J; Weinmann HJ
Invest Radiol; 2008 Dec; 43(12):817-28. PubMed ID: 19002053
[TBL] [Abstract][Full Text] [Related]
20. Thermodynamic stability and kinetic inertness of a Gd-DTPA bisamide complex grafted onto gold nanoparticles.
Mogilireddy V; Déchamps-Olivier I; Alric C; Laurent G; Laurent S; Vander Elst L; Muller R; Bazzi R; Roux S; Tillement O; Chuburu F
Contrast Media Mol Imaging; 2015; 10(3):179-87. PubMed ID: 25130910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
